Inmune Bio Inc stock (US45764T1060): Short interest rose in May

INMB ended the session at $1.39 on 05/29/2026, according to Robinhood's Nasdaq quote page, giving Inmune Bio a market capitalization of $38.02 million as investors continued to weigh liquidity, sentiment and pipeline risk in the U.S. biotech market.

For a second May data point, MarketBeat said short interest in INmune Bio rose to 3,641,628 shares as of 05/15/2026, up 2.9% from the previous report, a sign that bearish positioning remained elevated around the Nasdaq-listed name.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Inmune Bio Inc: core business model

Inmune Bio develops immunotherapies designed to reprogram the immune system for cancer and inflammatory disease research, making it a development-stage biotech rather than a revenue-scale commercial drug company.

Valuation metrics and multiples for Inmune Bio Inc

The available snapshot points to a market value of $38.02 million as of 05/29/2026, which places the stock squarely in micro-cap territory on Nasdaq. That scale matters because valuation in clinical-stage biotech is usually driven more by pipeline milestones, financing capacity and trial readouts than by sales or earnings multiples.

MarketBeat's short-interest update for 05/15/2026 showed 3.64 million shares sold short, equal to 17.34% of the float and roughly 5.3 days to cover, based on average volume of 479,553 shares. The same report said the short position rose 2.9% from the prior period, leaving INMB with a notably crowded bearish positioning profile for a small-cap biotechnology name.

In German-market terms, the stock also traded on Tradegate at an EUR quote could not be verified from the provided search set, so the article relies on the U.S. primary listing and quote data instead.

Conclusion

INMB's main market signal on 05/29/2026 was not a corporate event but a combination of a $1.39 share price and a persistent short-interest overhang on Nasdaq. For Friday's valuation focus, the key takeaway is that the stock's market narrative remains tied to pipeline optionality and trading positioning rather than to conventional earnings multiples.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.